WuXi PharmaTech announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab in support of Phase 2 and Phase 3 clinical trials globally. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States.
After rising 80% in the past seven months, Japan's benchmark Nikkei 225 stock index finally blinked. A staggering …